MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why INFU Stock advanced +0.91% Today — RQD Quant Desk Flash
$14.45 +0.91% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $14.51
InfuSystems Holdings Inc. (INFU) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $287.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $14.51 (+0.40%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 16.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk A
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INFU)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY INFU SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)
Altman Z-Score 5.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▲ #2 Bullish Driver: Macro Regime Fit+18/20 pts (24% of score)
FRED Regime × Technicals: 97% of 52W Range • RSI-14 at 58.6 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$13.56-1.2% Next Q
68
Q2 (-2Q)Grade B$13.40+4% Next Q
71
Q3 (-1Q)Grade B$13.94+3.7% Next Q
73
CurrentGrade B+$14.45+7.6% Hist 90D α
76
Trajectory: B- (68) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the INFU Bull Thesis Could Fail
Even with a 76/100 (B+) score, INFU faces multiple-compression risk if 43.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 53.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.97) or 200D SMA ($10.33) invalidates the momentum regime and cuts Target Base ($15.62) toward Bear Floor ($11.85).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INFU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INFU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INFU Stock advanced +0.91% Today — RQD Quant Desk Flash
InfuSystems Holdings Inc. (INFU) advanced +0.91% to $14.45, trading at 97% of its 52-week range ($7.29 – $14.64). High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 97% of its 52-week range ($7.29 – $14.64) with RSI-14 at 58.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.8% around $14.45 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 56% gross margin and $23.8M annual free cash flow.
Live INFU Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (INFU Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INFU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.65%▲ ASCENDING CHANNEL
2026-10-30O $14.45H $14.59L $13.92C $14.45VOL 130.3K
RES: $15.20SUP: $9.72SMA50: $12.97SMA200: $10.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INFU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
32.6%/yr Implied 5Y Growth
vs. +6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INFU today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INFU. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INFU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INFU)
Health Care Rank #36 of 1016
⚔️ ANIK vs INFU Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INFU vs. ANIK, OSUR, TMCI, CLPT)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, InfuSystems Holdings Inc. (INFU) ranks #36 by composite RQD confidence (76/100, grade B+) and #525 by equity capitalization ($287.8M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INFU
ACTIVE
InfuSystems Holdings Inc. | B+ | 76/100 | 43.4x | 56.0% | 12.8% | +0.91% | $287.8M | Benchmark Subject |
| ANIK Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | +1.11% | $291.6M | /anik-vs-infu → |
| OSUR OraSure Technologies Inc. | E | 32/100 | — | 41.9% | -35.0% | -0.49% | $281.4M | /osur-vs-infu → |
| TMCI Treace Medical Concepts Inc. | D- | 41/100 | — | 79.8% | -32.4% | +4.76% | $329.1M | /tmci-vs-infu → |
| CLPT ClearPoint Neuro Inc. | E | 34/100 | — | 61.4% | -35.0% | +1.23% | $342.7M | /clpt-vs-infu → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001337013In its most recent audited fiscal period (FY2025, filed 2025-12-31), InfuSystems Holdings Inc. (INFU) reported GAAP revenue of $143.4M (+6.4% vs. FY2024 revenue of $134.9M , and +14.0% cumulative change since FY2023) , GAAP net income of $6.6M, operating cash flow of $24.4M, and free cash flow of $23.8M (+23.1% YoY). On the balance sheet, INFU closed FY2025 with $100.6M in total assets against $19.6M in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $143.4M | $6.6M | $24.4M | $23.8M | $100.6M | $19.6M |
| FY2024 (FY) | 2024-12-31 | $134.9M | $2.3M | $20.5M | $19.4M | $103.6M | $23.9M |
| FY2023 (FY) | 2023-12-31 | $125.8M | $872.0K | $11.2M | $11.2M | — | — |
3. INFU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INFU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, InfuSystems Holdings Inc. (NYSE: INFU) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $14.45 (+0.91% 1D, market cap $287.8M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INFU ranks #36 in composite RQD confidence.
How does INFU compare to ANIK and OSUR in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), INFU carries a Roarable B+ (76/100 RQD), trailing P/E of 43.4x, gross margin of 56.0%, and ROIC of 12.8%. By comparison, ANIK (Anika Therapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M) and OSUR (OraSure Technologies Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INFU?
Per INFU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001337013), InfuSystems Holdings Inc. generated $143.4M in revenue (+6.4% YoY), $6.6M in net income, and $23.8M in free cash flow against $100.6M in total assets and $19.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INFU trading relative to its 50-day, 200-day, and 52-week technical levels?
INFU last traded at $14.45 (+0.91% on volume of 74,910 shares), positioning the stock +11.41% above its 50-day simple moving average ($12.97) and +39.88% above its 200-day simple moving average ($10.33). Across its 52-week range of $7.29 to $14.64, INFU sits at the 97.4% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($13.32 to $15.58).
INFU Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INFU stock moving today?
Why INFU Stock advanced +0.91% Today — RQD Quant Desk Flash. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support.